Shane Thomas Gleason Sells 9,923 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 9,923 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $2.55, for a total transaction of $25,303.65. Following the completion of the sale, the insider directly owned 1,116,806 shares in the company, valued at $2,847,855.30. This represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The shares were sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Trading Up 3.0%

NSPR traded up $0.03 during midday trading on Thursday, reaching $1.03. The company’s stock had a trading volume of 160,140 shares, compared to its average volume of 182,457. InspireMD, Inc. has a 1 year low of $0.97 and a 1 year high of $2.93. The stock’s 50-day moving average is $1.40 and its 200-day moving average is $1.68. The firm has a market capitalization of $48.24 million, a price-to-earnings ratio of -1.37 and a beta of 0.82.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NSPR. Maxim Group began coverage on InspireMD in a research note on Monday, February 2nd. They issued a “buy” rating and a $6.00 target price on the stock. Loop Capital set a $5.00 target price on InspireMD in a research note on Tuesday, February 24th. Piper Sandler reissued an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Finally, Lake Street Capital set a $4.00 target price on InspireMD in a research note on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $4.50.

InspireMD News Roundup

Here are the key news stories impacting InspireMD this week:

• Neutral Sentiment: Shane Thomas Gleason disclosed multiple recent sales of InspireMD shares, including transactions on May 19, May 23, May 27, May 29, May 30, and earlier January/February dates. Each filing says the sales were made to cover tax withholding obligations related to the vesting of equity awards, which makes the activity look more routine than a strategic exit. Article Title
• Neutral Sentiment: A new “Stock Forecast & Price Target” page for InspireMD may be contributing to increased trading interest, but the item itself does not include a specific rating change, earnings update, or business development that would clearly drive the shares. Article Title

Institutional Investors Weigh In On InspireMD

Several institutional investors have recently modified their holdings of NSPR. Aberdeen Group plc purchased a new position in InspireMD in the third quarter worth about $5,979,000. Rosalind Advisors Inc. boosted its position in InspireMD by 70.6% in the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after purchasing an additional 1,616,644 shares during the last quarter. Velan Capital Investment Management LP boosted its position in InspireMD by 137.1% in the third quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock worth $5,166,000 after purchasing an additional 1,239,669 shares during the last quarter. Parkman Healthcare Partners LLC boosted its position in InspireMD by 97.6% in the third quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock worth $5,882,000 after purchasing an additional 1,205,328 shares during the last quarter. Finally, Nantahala Capital Management LLC boosted its position in InspireMD by 45.7% in the third quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock worth $8,137,000 after purchasing an additional 1,058,467 shares during the last quarter. 44.78% of the stock is owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.